Evidence map›Paper›PMID 26181042›Full record

ArticlePloS one2015

Exploring the Benefits of Molecular Testing for Gonorrhoea Antibiotic Resistance Surveillance in Remote Settings.

Ben B Hui, Nathan Ryder, Jiunn-Yih Su, James Ward, Marcus Y Chen, Basil Donovan, Christopher K Fairley, Rebecca J Guy, Monica M Lahra, Mathew G Law and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Ben B HuiThe Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia.
Nathan RyderSexual Health and Blood Borne Virus Unit, Centre for Disease Control, Department of Health, Darwin, Northern Territory, Australia.
Jiunn-Yih SuSexual Health and Blood Borne Virus Unit, Centre for Disease Control, Department of Health, Darwin, Northern Territory, Australia.
James WardSouth Australian Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
Marcus Y ChenCentral Clinical School, Monash University, Melbourne, Victoria, Australia; Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia; School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Basil DonovanThe Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia; Sydney Sexual Health Centre, Sydney Hospital, Sydney, New South Wales, Australia.
Christopher K FairleyCentral Clinical School, Monash University, Melbourne, Victoria, Australia; Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia; School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Rebecca J GuyThe Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia.
Monica M LahraWHO Collaborating Centre for STD, Microbiology Department, South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Mathew G LawThe Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia.
David M WhileyQueensland Paediatric Infectious Diseases Laboratory, Queensland Children's Health Services, Queensland, Australia; Queensland Children's Medical Research Institute, University of Queensland, Queensland, Australia.
David G ReganThe Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia.
Northern Territory Health Services · AUMelbourne Sexual Health Centre · AUPrince of Wales Hospital · AUQueensland Children’s Medical Research Institute · AUSouth Australian Health and Medical Research Institute · AUSydney Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurveillance for gonorrhoea antimicrobial resistance (AMR) is compromised by a move away from culture-based testing in favour of more convenient nucleic acid amplification test (NAAT) tests. We assessed the potential benefit of a molecular resistance test in terms of the timeliness of detection of gonorrhoea AMR. METHODS AND

findingsAn individual-based mathematical model was developed to describe the transmission of gonorrhoea in a remote Indigenous population in Australia. We estimated the impact of the molecular test on the time delay between first importation and the first confirmation that the prevalence of gonorrhoea AMR (resistance proportion) has breached the WHO-recommended 5% threshold (when a change in antibiotic should occur). In the remote setting evaluated in this study, the model predicts that when culture is the only available means of testing for AMR, the breach will only be detected when the actual prevalence of AMR in the population has already reached 8 - 18%, with an associated delay of ~43 - 69 months between first importation and detection. With the addition of a molecular resistance test, the number of samples for which AMR can be determined increases facilitating earlier detection at a lower resistance proportion. For the best case scenario, where AMR can be determined for all diagnostic samples, the alert would be triggered at least 8 months earlier than using culture alone and the resistance proportion will have only slightly exceeded the 5% notification threshold.

conclusionsMolecular tests have the potential to provide more timely warning of the emergence of gonorrhoea AMR. This in turn will facilitate earlier treatment switching and more targeted treatment, which has the potential to reduce the population impact of gonorrhoea AMR.

Indexed as

AdolescentAdultAnti-Bacterial AgentsAustraliaBacterial Typing TechniquesDisease NotificationEpidemiological MonitoringFemaleGonorrheaHumansMaleMicrobial Sensitivity TestsNeisseria gonorrhoeaePenicillin ResistancePenicillinsPopulation GroupsAnti-Bacterial AgentsPenicillins

Identifiers

PMID26181042
PMCPMC4504484
OpenAlexW1709832311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.